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The	  conventional	  approach	  to	  developing	  disease-­‐modifying	  treatments	  for	  neurodegenerative	  
conditions	  has	  been	  to	  identify	  drivers	  of	  pathology	  and	  inhibit	  such	  pathways.	  Here	  we	  discuss	  the	  
possibility	  that	  the	  efficacy	  of	  such	  approaches	  may	  be	  increasingly	  attenuated	  as	  disease	  
progresses.	  This	  is	  based	  on	  experiments	  using	  a	  mouse	  models	  of	  spinocerebellar	  ataxia	  type	  1	  and	  
Huntington’s	  disease,	  where	  expression	  of	  the	  dominantly	  acting	  mutations	  could	  be	  switched	  off,	  as	  
well	  as	  studies	  in	  human	  Huntington’s	  disease,	  which	  suggest	  that	  the	  primary	  genetic	  driver	  of	  age-­‐
of-­‐onset	  of	  disease	  is	  a	  much	  weaker	  determinant	  of	  disease	  progression	  in	  affected	  individuals.	  The	  
idea	  that	  one	  may	  approach	  a	  point	  in	  the	  disease	  course	  where	  such	  rational	  therapeutic	  strategies	  
based	  on	  targets	  which	  determine	  onset	  of	  disease	  have	  minimal	  efficacy,	  suggests	  that	  one	  needs	  
to	  consider	  other	  approaches	  to	  therapies	  and	  clinical	  trial	  design,	  including	  initiation	  of	  therapies	  in	  
presymptomatic	  individuals.	  	  
	  
Introduction	  
The	  increasing	  human	  life	  expectancies	  coupled	  with	  the	  age-­‐dependent	  risk	  for	  most	  
neurodegenerative	  diseases	  has	  focussed	  attention	  on	  developing	  therapies	  for	  common	  polygenic	  
conditions	  like	  Alzheimer’s	  and	  Parkinson’s	  disease,	  as	  well	  as	  monogenic	  conditions	  like	  
Huntington’s	  disease	  and	  certain	  spinocerebellar	  ataxias.	  The	  strategy	  that	  has	  been	  considered	  
most	  widely	  has	  been	  to	  identify	  mechanistic	  drivers	  of	  pathogenesis	  and	  develop	  agents	  that	  
interfere	  with	  these	  putative	  disease-­‐causing	  pathways.	  Such	  strategies	  require	  that	  the	  disease	  
processes	  do	  not	  reach	  a	  stage	  where	  such	  mechanistic	  intervention	  strategies	  are	  ineffective.	  
In	  some	  other	  disease	  scenarios,	  this	  consideration	  is	  relevant.	  For	  example,	  if	  a	  physician	  in	  the	  
emergency	  room	  is	  confronted	  with	  a	  patient	  in	  cardiac	  failure	  due	  to	  severe	  coronary	  artery	  disease	  
caused	  by	  raised	  cholesterol	  levels,	  then	  the	  priority	  is	  not	  to	  reduce	  the	  cholesterol	  levels,	  but	  to	  




plan	  of	  the	  symptomatic	  patient	  is	  not	  directed	  primarily	  at	  the	  primary	  cause	  of	  disease,	  it	  is	  likely	  
that	  long	  term-­‐treatment	  with	  cholesterol	  lowering	  drugs,	  like	  statins,	  for	  years	  prior	  to	  the	  
predicted	  age	  of	  disease	  onset,	  would	  have	  been	  effective	  in	  reducing	  the	  risk	  of	  disease	  and/or	  
delaying	  its	  onset.	  In	  various	  autoimmune	  diseases,	  there	  have	  been	  suggestions	  that	  there	  are	  
important	  genetic	  determinants	  of	  disease	  course	  that	  are	  distinct	  from	  the	  loci	  that	  influence	  risk	  of	  
disease	  manifestation,	  reinforcing	  the	  concept	  that	  the	  biology	  of	  disease	  progression	  may	  be	  
different	  to	  that	  of	  disease	  initiation	  [1].	  Thus,	  in	  such	  diseases,	  the	  optimal	  targets	  for	  therapy	  may	  
be	  the	  determinants	  of	  disease	  progression,	  rather	  than	  the	  causes	  of	  disease	  presentation.	  
	  
Approaching	  points	  of	  no	  return	  in	  a	  neurodegenerative	  disease	  mouse	  
model	  
In	  neurodegenerative	  disease,	  a	  point	  of	  no	  return	  is	  reached	  once	  a	  substantial	  number	  of	  neurons	  
have	  died.	  However,	  the	  possibility	  that	  this	  scenario	  may	  exist	  in	  neurodegenerative	  diseases	  
before	  neuronal	  death	  is	  important	  to	  consider,	  as	  it	  may	  have	  major	  ramifications	  for	  treatment	  
strategies,	  as	  well	  as	  for	  clinical	  trials,	  which	  are	  expensive	  and	  time	  consuming.	  Our	  concerns	  are	  
stimulated	  by	  a	  number	  of	  studies.	  Perhaps	  the	  most	  powerful	  strategy	  to	  address	  this	  question	  in	  
the	  preclinical	  setting	  is	  to	  switch	  on	  and	  off	  a	  genetic	  factor	  that	  causes	  disease	  in	  a	  model	  
organism.	  This	  experiment	  has	  been	  done	  in	  a	  mouse	  model	  of	  spinocerebellar	  ataxia	  type	  1,	  an	  
autosomal	  dominant	  neurodegenerative	  disease,	  which	  is	  caused	  by	  a	  polyglutamine	  expansion	  
mutation	  in	  the	  ataxin	  1	  gene.	  It	  is	  one	  of	  the	  nine	  known	  diseases	  caused	  by	  such	  mutations,	  the	  
most	  common	  which	  is	  Huntington’s	  disease.	  Overexpression	  of	  mutant	  ataxin	  1	  in	  the	  cerebellar	  
Purkinje	  cells	  (which	  are	  a	  prominent	  target	  of	  the	  human	  disease)	  is	  sufficient	  to	  cause	  
abnormalities	  in	  the	  dendritic	  arborisation	  and	  spine	  densities	  in	  these	  cells	  and	  abnormalities	  in	  the	  
Purkinje	  cell-­‐parallel	  fibre	  synapses,	  which	  are	  associated	  with	  loss	  of	  coordination/motor	  




and	  motor	  abnormalities	  were	  assessed	  using	  a	  rotarod	  test,	  which	  places	  the	  mice	  on	  a	  rotating	  
cylinder	  and	  measures	  how	  long	  the	  mice	  stay	  on	  this	  apparatus	  before	  falling	  off.	  Thus,	  in	  these	  
mice,	  the	  disease	  is	  caused	  by	  the	  presence	  of	  the	  transgenic	  protein.	  To	  address	  whether	  mice	  
could	  recover	  after	  the	  initiation	  of	  disease,	  a	  model	  was	  generated	  where	  the	  transgene	  could	  be	  
conditionally	  switched	  off	  using	  a	  tetracycline-­‐regulatable	  system.	  This	  was	  done	  in	  early,	  mid	  and	  
late	  disease	  in	  the	  mice	  –	  in	  all	  cases	  prior	  to	  Purkinje	  cell	  loss.	  In	  the	  early	  disease,	  switching	  off	  the	  
transgene	  essentially	  led	  to	  a	  recovery	  of	  both	  the	  motor	  and	  Purkinje	  cell	  morphological	  
abnormalities.	  In	  contrast	  to	  the	  complete	  recovery	  assessed	  by	  these	  measures	  in	  early	  disease,	  the	  
improvement	  in	  mid-­‐disease	  after	  switching	  off	  the	  transgene	  was	  partial.	  However,	  in	  advanced	  
disease,	  the	  mice	  failed	  to	  show	  a	  significant	  improvement	  on	  the	  rotarod	  test	  and	  while	  there	  was	  
some	  improvement	  in	  Purkinje	  cell	  morphology,	  this	  was	  still	  abnormal	  after	  switch-­‐off.	  Thus,	  as	  
disease	  progresses	  in	  this	  model,	  the	  ability	  to	  return	  to	  normal	  is	  severely	  attenuated	  after	  removal	  
of	  the	  primary	  causative	  agent,	  mutant	  ataxin	  1.	  This	  could	  not	  be	  attributed	  to	  failure	  to	  switch	  off	  
the	  transgene	  or	  remove	  the	  mutant	  protein	  [2]	  (Figure	  1).	  
	  
Another	  approach	  to	  switching	  of	  the	  transgene	  is	  to	  use	  single	  stranded	  antisense	  oligonucleotides.	  
In	  an	  Huntington’s	  disease	  model,	  initiation	  of	  such	  treatment	  at	  3	  months	  of	  age	  led	  to	  a	  better	  
phenotypic	  improvement	  than	  when	  treatment	  was	  started	  at	  6	  months	  of	  age	  [3].	  It	  will	  be	  
interesting	  to	  study	  this	  phenomenon	  in	  other	  disease	  models	  in	  mice	  which	  may	  be	  amenable	  to	  
such	  manipulations.	  However,	  there	  may	  be	  clues	  that	  suggest	  a	  point-­‐of	  no	  return	  in	  human	  
neurodegenerative	  diseases.	  The	  most	  obvious	  suggestion	  comes	  from	  diseases	  like	  Parkinson’s	  
disease,	  where	  there	  can	  be	  major	  loss	  of	  the	  most	  vulnerable	  neuronal	  populations	  prior	  to	  disease	  
onset	  [4].	  Significant	  neuronal	  loss	  also	  occurs	  in	  forms	  of	  Alzheimer’s	  disease	  and	  Huntington’s	  
disease	  prior	  to	  clinical	  manifestation	  [5].	  Again,	  if	  one	  accepts	  that	  it	  may	  be	  impossible	  to	  recover	  
such	  neuronal	  loss,	  then	  this	  will	  set	  a	  baseline	  beyond	  which	  further	  improvement	  may	  not	  be	  




to	  neuronal	  dysfunction,	  which	  may	  be	  rescuable	  to	  some	  extent,	  and	  may	  vary	  from	  neuron	  to	  
neuron.	  Furthermore,	  there	  may	  be	  non-­‐cell-­‐autonomous	  factors	  that	  contribute	  to	  disease,	  some	  of	  
which	  may	  be	  more	  reversible	  than	  others.	  
	  
Genetic	  studies	  in	  Huntington’s	  disease	  uncouple	  polyglutamine	  length	  from	  
disease	  duration	  
Genetic	  studies	  have	  also	  informed	  this	  question.	  In	  Huntington	  disease	  (HD),	  as	  in	  the	  other	  
polyglutamine	  diseases,	  the	  number	  of	  glutamine	  residues	  in	  the	  polyglutamine	  tract	  is	  inversely	  
correlated	  with	  age-­‐at-­‐onset.	  The	  polyglutamines	  are	  encoded	  by	  a	  CAG	  triplet	  repeat	  expansion	  in	  
the	  gene.	  	  In	  Huntington	  disease,	  the	  CAG	  number	  accounts	  for	  about	  70%	  of	  the	  variance	  in	  age-­‐at-­‐
onset	  [6].	  Thus,	  in	  HD,	  one	  has	  a	  paradigm	  where	  one	  can	  examine	  the	  “severity”	  of	  the	  disease–
causing	  monogenic	  mutation	  in	  relation	  to	  disease	  progression.	  For	  example,	  if	  one	  were	  to	  assume	  
that	  the	  CAG	  were	  as	  strong	  a	  determinant	  of	  disease	  progression	  as	  for	  onset,	  then	  one	  idealised	  
therapy	  for	  such	  diseases	  would	  be	  to	  reduce	  the	  CAG	  repeat	  length	  via	  some	  type	  of	  genetic	  editing	  
strategy.	  Even	  if	  one	  could	  not	  reduce	  the	  repeat	  length	  to	  below	  the	  disease	  threshold,	  a	  modest	  
reduction	  in	  CAG	  repeat	  length	  would	  be	  predicated	  to	  have	  a	  significant	  impact.	  	  
Surprisingly,	  in	  HD,	  the	  duration	  of	  disease,	  i.e.	  time	  from	  onset	  to	  death,	  is	  not	  correlated	  with	  
polyglutamine	  length	  [7].	  	  This	  led	  the	  authors	  to	  two	  possible	  models,	  which	  they	  articulated	  
elegantly,	  as	  follows.	  Either	  “(1)	  HD	  pathogenesis	  is	  driven	  by	  mutant	  huntingtin,	  but	  before	  or	  near	  
motor	  onset,	  sufficient	  CAG-­‐driven	  damage	  occurs	  to	  permit	  CAG-­‐independent	  processes	  and	  then	  
lead	  to	  eventual	  death.	  In	  this	  scenario,	  some	  pathological	  changes	  and	  their	  clinical	  correlates	  could	  
still	  worsen	  in	  a	  CAG-­‐driven	  manner	  after	  disease	  onset,	  but	  these	  CAG-­‐related	  progressive	  changes	  
do	  not	  themselves	  determine	  duration.	  Alternatively,	  (2)	  HD	  pathogenesis	  is	  driven	  by	  mutant	  
huntingtin	  acting	  in	  a	  CAG-­‐dependent	  manner	  with	  different	  time	  courses	  in	  multiple	  cell	  types,	  and	  




scenario,	  processes	  driven	  by	  HTT	  CAG	  length	  lead	  directly	  to	  death	  but	  not	  via	  the	  striatal	  pathology	  
associated	  with	  motor	  manifestations”	  [7].	  	  Interestingly,	  this	  same	  group	  has	  identified	  a	  few	  loci	  
distinct	  from	  the	  CAG	  repeats	  in	  huntingtin	  that	  contribute	  to	  some	  of	  the	  residual	  variability	  in	  age-­‐
at-­‐onset	  that	  is	  not	  accounted	  for	  by	  the	  repeats.	  They	  analysed	  the	  locus	  with	  strongest	  effect,	  
which	  also	  did	  not	  affect	  disease	  duration,	  again	  suggesting	  a	  critical	  dissociation	  [6].	  But	  does	  the	  
CAG/polyglutamine	  repeat	  number	  determine	  disease	  course,	  which	  may	  be	  distinct	  from	  disease	  
duration	  (although	  this	  would	  not	  be	  the	  most	  parsimonious	  model)?	  This	  is	  critical	  to	  answer	  in	  
terms	  of	  the	  therapeutic	  strategy.	  	  
This	  issue	  has	  been	  previously	  addressed	  in	  HD.	  As	  clinical	  features	  of	  progression	  may	  be	  difficult	  to	  
assess,	  this	  was	  done	  with	  standardised	  clinical	  scales	  [8].	  While	  one	  may	  argue	  that	  such	  scales	  may	  
lack	  sensitivity	  and	  be	  prone	  to	  noise,	  it	  is	  important	  to	  point	  out	  that	  the	  definition	  of	  a	  precise	  age-­‐
at-­‐onset	  for	  a	  disease	  with	  an	  insidious	  initiation	  may	  be	  similarly	  noisy.	  It	  appears	  that	  CAG	  repeat	  
number	  only	  affects	  disease	  progression	  when	  one	  corrects	  for	  age-­‐at-­‐onset	  –	  an	  older	  age	  of	  onset	  
appears	  to	  increase	  the	  rate	  of	  progression.	  Indeed,	  CAG	  number	  appears	  to	  explain	  about	  20%	  of	  
the	  variation	  of	  disease	  duration	  at	  the	  time	  of	  institutionalisation	  (and	  CAG	  repeat	  length	  correlated	  
inversely	  with	  this	  duration).	  	  However,	  this	  was	  only	  apparent	  if	  one	  corrected	  for	  age	  at	  onset	  [9].	  
Since	  the	  CAG	  repeat	  number	  accounts	  for	  approximately	  70%	  of	  the	  variance	  of	  age-­‐at-­‐onset,	  this	  
would	  be	  compatible	  with	  the	  concept	  that	  the	  severity	  of	  the	  primary	  mutation	  in	  terms	  of	  its	  effect	  
on	  onset	  is	  much	  greater	  than	  its	  effect	  on	  disease	  course.	  	  
One	  may	  also	  be	  able	  to	  learn	  from	  large	  prospective	  studies	  that	  have	  examined	  both	  neuroimaging	  
and	  clinical	  parameters.	  In	  the	  TRACK-­‐HD	  study,	  the	  CAG	  repeat	  length	  had	  less	  predictive	  power	  for	  
such	  measures	  in	  early	  HD	  patients	  than	  in	  presymptomatic	  HD	  mutation	  carriers	  for	  the	  net	  
changes	  assessed	  over	  a	  36	  month	  period	  [10].	  While	  such	  differences	  may	  be	  due	  to	  ceiling	  and	  
floor	  effects	  of	  the	  measures	  used,	  these	  factors	  cannot	  	  explain	  why	  the	  CAG	  repeats	  in	  early	  HD	  




presymptomatic	  cases.	  For	  all	  parameters	  and	  in	  all	  groups,	  the	  correlation	  coefficients	  versus	  CAG	  
length	  were	  much	  less	  than	  0.7,	  again	  consistent	  with	  the	  idea	  that	  disease	  progression	  correlates	  
less	  with	  repeat	  length	  than	  disease	  onset.	  
While	  these	  data	  and	  the	  other	  papers	  discussed	  above	  do	  not	  demonstrate	  that	  there	  is	  a	  point	  of	  
no	  return	  for	  therapy	  of	  such	  diseases,	  they	  are	  consistent	  with	  the	  concept	  that	  the	  ability	  to	  treat	  
such	  diseases	  by	  modulating	  the	  primary	  drivers	  of	  onset	  will	  wane	  as	  disease	  progresses.	  This	  is	  not	  
unexpected,	  due	  to	  the	  increased	  cell	  loss	  and	  pathway	  perturbation.	  This	  may	  vary	  from	  disease	  to	  
disease.	  Ultimately,	  the	  question	  can	  only	  be	  tested	  definitively	  in	  humans	  with	  strategies	  like	  
antisense	  reduction	  of	  mutant	  proteins	  in	  autosomal	  dominant	  diseases	  like	  Huntington’s	  disease,	  
assuming	  one	  can	  achieve	  sufficient	  knockdown	  across	  all	  the	  relevant	  areas	  in	  human	  brains.	  
	  
Human	  trial	  in	  a	  neurodegenerative	  protein-­‐misfolding	  disease	  reveals	  
greater	  efficacy	  when	  treatment	  is	  initiated	  early	  
Important	  lessons	  about	  the	  timing	  of	  such	  clinical	  trials	  may	  be	  suggested	  by	  studies	  in	  the	  
neurodegenerative	  protein	  misfolding	  disease,	  transthyretin	  familial	  amyloid	  polyneuropathy	  (TTR-­‐
FAP).	  TTR-­‐FAP	  is	  caused	  by	  autosomal	  dominant	  TTR	  gene	  mutations,	  which	  destabilise	  the	  
tetramers	  of	  the	  transthyretin	  (TTR)	  protein.	  This	  ultimately	  leads	  to	  misfolding	  of	  the	  monomers	  
and	  aggregation/amyloidogenesis	  [11].	  TTR	  is	  a	  plasma	  protein	  mainly	  derived	  from	  the	  liver	  and	  its	  
aggregated	  forms	  in	  TTR-­‐FAP	  are	  associated	  with	  axonal	  degeneration,	  which	  causes	  progressive	  
sensorimotor	  and	  autonomic	  neuropathy	  [11].	  Tafamidis	  has	  been	  shown	  to	  stabilise	  the	  mutant	  TTR	  
tetramers	  and	  has	  been	  tested	  in	  patients.	  In	  an	  interesting	  study	  which	  followed	  a	  double-­‐blind	  trial	  
of	  this	  drug	  with	  an	  open	  label	  study	  in	  both	  the	  previously-­‐treated	  and	  placebo	  groups,	  the	  authors	  
found	  that	  earlier	  treatment	  enabled	  more	  effective	  responses	  than	  delayed	  treatment	  as	  




common	  CNS-­‐focussed	  protein-­‐misfolding	  diseases,	  its	  similarities	  hint	  at	  the	  likelihood	  that	  earlier	  
initiation	  of	  therapies	  may	  have	  better	  outcomes	  even	  in	  such	  human	  conditions.	  	  	  
	  
We	  believe	  that	  the	  likelihood	  of	  diminishing	  return	  with	  disease	  progression	  for	  mechanistic	  
therapeutic	  strategies	  should	  stimulate	  alternative	  strategies.	  As	  with	  certain	  autoimmune	  diseases,	  
there	  may	  be	  targets	  for	  disease	  progression	  that	  differ	  from	  those	  causing	  onset	  [13].	  It	  is	  difficult	  
to	  know	  what	  these	  targets	  may	  be.	  However,	  these	  could	  include	  neuronal	  network	  disturbances	  
caused	  by	  cell	  death,	  and	  glial	  abnormalities.	  Some	  of	  these	  targets	  may	  be	  identifiable	  by	  genetic	  
approaches	  in	  large	  scale	  cohorts.	  A	  better	  understanding	  of	  these	  processes	  will	  be	  critical	  for	  
developing	  disease-­‐modifying	  strategies	  for	  patients	  with	  established	  disease.	  
	  
The	  ideal	  scenario	  to	  work	  towards	  is	  to	  delay	  disease	  onset.	  In	  monogenic	  diseases	  like	  HD,	  most	  
individuals	  at	  risk	  will	  have	  a	  family	  history	  and	  one	  could	  start	  a	  preventive	  drug/agent	  many	  years	  
prior	  to	  the	  anticipated	  age-­‐at-­‐onset	  with	  the	  aim	  of	  delaying	  disease	  eventually	  beyond	  the	  normal	  
human	  lifespan.	  For	  complex	  diseases	  like	  Alzheimer	  and	  Parkinson	  disease,	  one	  may	  strive	  towards	  
identifying	  a	  protective	  pathway	  that	  can	  have	  modest	  effects	  over	  many	  years.	  For	  example,	  if	  one	  
were	  to	  identify	  a	  drug	  analogous	  to	  statins	  for	  heart	  disease	  that	  delayed	  the	  onset	  of	  Alzheimer’s	  
disease	  by	  even	  only	  one	  year,	  then	  the	  impact	  on	  individuals,	  families	  and	  health	  services	  would	  be	  
huge,	  given	  the	  prevalence	  of	  the	  condition.	  	  
	  
Conclusions	  
For	  both	  complex	  and	  monogenic	  diseases,	  we	  believe	  that	  strategies	  that	  delay	  the	  onset	  of	  disease	  
should	  be	  considered	  –	  thus,	  one	  will	  need	  to	  identify	  biomarkers	  of	  pathological	  progression	  prior	  
to	  onset	  and	  test	  these.	  	  This	  challenging	  task	  may	  be	  simplified	  in	  some	  cases	  by	  studying	  




international	  registry	  of	  individuals	  at	  risk	  for	  developing	  autosomal	  dominant	  Alzheimer’s	  disease	  
(ADAD),	  has	  embarked	  on	  an	  ambitious	  plan	  to	  longitudinally	  assess	  asymptomatic	  and	  symptomatic	  
ADAD	  mutation	  carriers	  and	  their	  non-­‐carrier	  siblings	  (genetically	  similar	  controls)	  	  for	  clinical,	  
cognitive,	  and	  imaging	  and	  fluid	  biomarkers.	  This	  has	  the	  prospect	  of	  identifying	  biomarkers	  that	  
precede	  disease	  and	  the	  ability	  to	  perform	  “preventive”	  trials	  in	  such	  cases	  [14].	  Data	  from	  such	  
studies	  will	  likely	  inform	  “sporadic”	  Alzheimer’s	  disease.	  Similar	  studies	  are	  underway	  in	  
Huntington’s	  disease	  (TRACK-­‐HD),	  where	  recent	  imaging	  studies	  in	  presymptomatic	  HD	  gene	  carriers	  
suggest	  that	  this	  may	  be	  an	  amenable	  strategy	  conditions	  [10].	  One	  needs	  to	  acknowledge	  that	  the	  
biological	  power	  to	  detect	  the	  impact	  of	  a	  mechanistic	  therapeutic	  intervention	  is	  likely	  to	  diminish	  
with	  disease	  course.	  The	  corollary	  of	  this	  is	  that	  such	  strategies	  may	  be	  missed	  when	  symptomatic	  
individuals	  are	  tested	  and	  discarded,	  while	  they	  may	  be	  powerful	  when	  initiated	  prior	  to	  disease	  
onset.	  Finally,	  strategies	  with	  modest	  defects	  may	  have	  big	  impacts,	  if	  they	  can	  be	  administered	  over	  
many	  years	  prior	  to	  the	  expected	  onset	  of	  disease.	  We	  appreciate	  that	  such	  proposed	  studies	  in	  
asymptomatic	  patients	  using	  surrogate	  biomarkers	  as	  endpoints	  will	  raise	  issues	  from	  a	  regulatory	  
perspective.	  However,	  the	  potential	  benefits	  of	  such	  a	  strategy	  may	  heavily	  outweigh	  the	  risks.	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Figure	  legend	  
Figure	  1.	  Points	  of	  no-­‐recovery	  in	  neurodegenerative	  disease.	  	  With	  increasing	  age	  and	  disease	  
duration	  neuronal	  pathology	  progressively	  worsens,	  reaching	  a	  point	  where	  neuronal	  death	  ensues	  
(A).	  During	  this	  period	  there	  is	  a	  decline	  in	  neurological	  status	  (B)	  and	  alterations	  in	  gene	  expression	  
and	  physiology	  (C).	  Changes	  in	  gene	  expression	  typically	  fall	  into	  two	  categories,	  those	  associated	  
with	  disease	  progression	  –	  solid	  triangle	  –	  and	  those	  largely	  reflecting	  neuronal	  loss	  –	  hatched	  box.	  
Changes	  in	  A-­‐C	  impact	  ability	  of	  therapeutic	  approaches	  to	  impact	  disease	  progression	  and	  induce	  
recovery	  (D).	  During	  early	  phase	  of	  disease	  there	  is	  a	  period	  when	  mechanistic	  therapeutic	  
approaches	  are	  effective,	  but	  with	  diminishing	  effect	  with	  age	  –	  green	  triangle.	  With	  neuronal	  death	  
a	  point	  of	  no-­‐return	  is	  reached	  –	  red	  bar.	  It	  is	  proposed	  that	  an	  initial	  point	  of	  no-­‐recovery	  occurs	  
prior	  to	  neuronal	  death	  –	  hatched	  red	  bar	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